Items where authors include "Hinsley, S"

Article

Brown, SR orcid.org/0000-0002-7975-7537, Hinsley, S, Hall, E et al. (5 more authors) (2022) A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations. Clinical Cancer Research, 28 (17). pp. 3639-3651. ISSN 1078-0432

Walls, GM, Oughton, JB orcid.org/0000-0002-2047-804X, Chalmers, AJ et al. (20 more authors) (2020) CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology, 25. pp. 61-66. ISSN 2405-6308

Hinsley, S, Walker, K, Sherratt, D et al. (13 more authors) (2020) The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 21 (1). 826. 826-.

Wilson, C, Bell, R, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (5 more authors) (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 94. pp. 70-78. ISSN 0959-8049

Brown, J, Rathbone, E, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (13 more authors) (2018) Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. Journal of the National Cancer Institute, 110 (8). pp. 871-879. ISSN 0027-8874

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Alberro, JA, Ballester, B et al. (596 more authors) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19 (1). pp. 27-39. ISSN 1470-2045

Wilson, C, Hinsley, S orcid.org/0000-0001-6903-4688, Marshall, H et al. (4 more authors) (2017) Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – an AZURE (BIG 01/04) sub-study. Journal of Bone Oncology, 9. pp. 48-54. ISSN 2212-1374

Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688, Ballesteros, M et al. (11 more authors) (2016) The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC hematology, 16. p. 14. ISSN 2052-1839

Snee, MP, McParland, L, Collinson, F et al. (10 more authors) (2016) The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Pilot and Feasibility Studies, 2 (1). 5.

Kroep, JR, Charehbili, A, Coleman, RE et al. (10 more authors) (2016) Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. European Journal of Cancer, 54. pp. 57-63. ISSN 0959-8049

Murray, L, Karakaya, E, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (8 more authors) (2016) Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity. The British Journal of Radiology, 89 (1058). 20150628. ISSN 0007-1285

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman, R, Powles, T et al. (102 more authors) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, 386 (10001). 1353 - 1361. ISSN 0140-6736

Kroep, JR, Charehbili, A, Coleman, RE et al. (10 more authors) (2015) Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Cancer Research, 75 (9). Abstract P3-11-04. ISSN 0008-5472

Coleman, R, Cameron, D, Dodwell, D et al. (13 more authors) (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology, 15 (9). 997 - 1006. ISSN 1470-2045

Coleman, R, Hinsley, S orcid.org/0000-0001-6903-4688, Bell, R et al. (7 more authors) (2013) Adjuvant therapy in early breast cancer with zoledronic acid (AZURE - BIG 01/04): Final efficacy analysis. European Journal of Cancer, 49 (Suppl 3). S5-S5. ISSN 0959-8049

Proceedings Paper

Sherborne, AL, Shah, V, Ellis, S et al. (15 more authors) (2017) Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. In: Blood. 59th ASH Annual Meeting and Exposition, 09-12 Dec 2017, Atlanta, GA, USA. American Society of Hematology , p. 1767.

Yong, KL, Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (8 more authors) (2015) Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen. In: Blood. 57th ASH Annual Meeting and Exposition, 05-08 Dec 2015, Orlando, FL, USA. American Society of Hematology .